Retatrutide side effects and libido changes are increasingly discussed as this investigational triple receptor agonist advances through clinical trials for obesity and type 2 diabetes. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors — a mechanism that sets it apart from approved medicines such as semaglutide and tirzepatide. While early Phase 2 data show a promising efficacy profile, the full side effect picture is still emerging. This article outlines what is currently known about retatrutide's adverse effects, addresses questions around libido and sexual health, and explains when to seek medical advice in the UK context.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, and currently in Phase 2 and Phase 3 clinical trials.

Retatrutide is an investigational medicine currently under clinical development for the treatment of obesity and type 2 diabetes. It belongs to a novel class of agents known as triple receptor agonists, targeting three key hormonal receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCGR) receptor. This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist).

By activating the GLP-1 receptor, retatrutide is thought to promote insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite — effects that collectively support blood glucose control and weight reduction. The additional activation of the GIP receptor may further support insulin action and fat metabolism, although the precise contribution of GIP agonism in humans remains an area of active research. The glucagon receptor component is hypothesised to increase energy expenditure and promote fat breakdown (lipolysis), potentially contributing to the substantial weight loss observed in early-phase trials; however, glucagon receptor agonism can also raise blood glucose, and the net metabolic effect in this triple combination is still being characterised. The relative contributions of each receptor to overall efficacy and tolerability are under ongoing investigation.

As of 2024–2025, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It is currently in Phase 2 and Phase 3 clinical trials (see ClinicalTrials.gov for current study listings), meaning it is not available as a licensed treatment in the UK. Any use outside of a formal clinical trial setting would be considered unlicensed and is not endorsed by NICE or NHS guidance. Patients should be aware that information about its side effect profile is still emerging and is based primarily on trial data rather than long-term real-world evidence.

Common and Reported Side Effects of Retatrutide

The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — with no confirmed clinical signal linking retatrutide specifically to libido changes in published trial data.

Based on Phase 2 clinical trial data published in The New England Journal of Medicine (Jastreboff et al., 2023), retatrutide shares a side effect profile broadly consistent with other GLP-1-based therapies, though the triple receptor mechanism may introduce additional considerations.

Commonly reported side effects include:

• Gastrointestinal symptoms — nausea, vomiting, diarrhoea, and constipation are the most frequently reported adverse effects, particularly during dose escalation. Persistent vomiting or diarrhoea can lead to dehydration, which in some cases may affect kidney function. If you are unable to keep fluids down, seek prompt medical advice.

• Reduced appetite — while therapeutically intended, this can occasionally lead to inadequate nutritional intake

• Injection site reactions — mild redness, bruising, or discomfort at the site of subcutaneous injection

• Fatigue and dizziness — reported in a subset of trial participants, often associated with early treatment phases

• Hypoglycaemia (low blood sugar) — uncommon with retatrutide alone, but the risk increases when it is used alongside insulin or sulfonylureas. If you experience shakiness, sweating, confusion, or palpitations, seek medical advice promptly.

• Small increases in heart rate — modest mean increases in resting heart rate have been observed with incretin-based therapies as a class; clinical significance in individual patients should be assessed by a clinician

• Gallbladder-related problems — cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported with GLP-1 receptor agonist class medicines. Symptoms include sudden pain in the upper right abdomen, fever, jaundice (yellowing of the skin or eyes), pale stools, or dark urine. These symptoms require prompt medical assessment.

• Hypersensitivity reactions — rare allergic reactions have been reported with incretin-class medicines. Signs include rash, swelling of the face or throat, or difficulty breathing, which require urgent medical attention.

Regarding libido and sexual function: some individuals using GLP-1 receptor agonists and related weight-loss medicines have anecdotally reported changes in libido — both increases and decreases — across online patient communities and in broader discussions about the drug class. However, there is no confirmed clinical signal linking retatrutide specifically to changes in libido in published trial data. Libido changes, if they occur, are more likely to reflect indirect factors such as significant weight loss, associated hormonal shifts, fatigue, nausea, or psychological changes related to body image, rather than a direct pharmacological effect. These distinctions are important when interpreting individual experiences.

Pregnancy and breastfeeding: as an investigational medicine, retatrutide has not been studied in pregnancy or breastfeeding. Anyone who is pregnant, planning a pregnancy, or breastfeeding should seek medical advice and avoid investigational medicines unless specifically directed by a clinician. Trial participants should notify their study team immediately if pregnancy occurs.

What the Current Evidence Says About These Effects

There is currently no peer-reviewed clinical evidence directly linking retatrutide to changes in libido; any such changes are more likely related to weight loss, hormonal shifts, or psychological factors.

The evidence base for retatrutide remains limited compared to fully licensed medicines, given its investigational status. Phase 2 trial data (Jastreboff et al., NEJM, 2023) demonstrated substantial weight reduction — participants lost a mean of approximately 24% of body weight over 48 weeks at the highest doses — alongside improvements in cardiometabolic markers. However, the trials were not specifically designed to assess sexual health outcomes, and libido was not a primary or secondary endpoint in published studies.

In the broader GLP-1 receptor agonist literature, there is growing interest in the relationship between these medicines and hormonal or sexual health. Some research suggests that weight loss itself — regardless of the method — can improve testosterone levels in men with obesity and restore menstrual regularity in women with polycystic ovary syndrome (PCOS) (see NICE NG227: Polycystic ovary syndrome — diagnosis and management), both of which may positively influence libido. Conversely, significant energy deficit and rapid weight loss can temporarily suppress reproductive hormones — a phenomenon recognised in functional hypothalamic amenorrhoea — potentially reducing sexual drive in some individuals (see NICE CKS: Amenorrhoea).

For retatrutide specifically, there is currently no peer-reviewed clinical evidence directly linking the drug to changes in libido, either as an adverse effect or a benefit. The glucagon receptor agonism component is relatively novel in this context, and its downstream effects on the hypothalamic-pituitary-gonadal axis — which governs sex hormone production — have not been formally studied in published retatrutide trials.

It is also worth noting that psychological wellbeing, self-esteem, and relationship dynamics can all shift during significant weight loss journeys, and these factors may independently influence sexual interest. Clinicians and patients should therefore approach reports of libido changes with nuance, considering the full clinical picture rather than attributing such changes solely to the medication.

When to Speak to a GP or Specialist

Seek immediate emergency care for severe abdominal pain, signs of anaphylaxis, or severe dehydration; contact your GP for persistent nausea, mood changes, libido disturbance, or hormonal symptoms.

Because retatrutide is not yet licensed in the UK, individuals who are participating in clinical trials or who have accessed the drug through other means should maintain open communication with a qualified healthcare professional. Any new or unexpected symptoms should be discussed promptly, and self-management without medical oversight is strongly discouraged.

Call 999 or go to your nearest A&E immediately if you experience:

• Severe abdominal pain with vomiting that does not settle — this may indicate pancreatitis or a serious gallbladder problem

• Signs of a severe allergic reaction (anaphylaxis) — including swelling of the face, lips, or throat, difficulty breathing, or a widespread rash

• Severe dehydration with inability to keep any fluids down

Contact NHS 111 or seek urgent medical advice if you experience:

• Sudden pain in the upper right abdomen, fever, jaundice, pale stools, or dark urine — possible signs of gallbladder disease

• Persistent vomiting or diarrhoea that is preventing adequate fluid intake

Contact your GP or specialist if you experience:

• Persistent or troublesome nausea, vomiting, or abdominal discomfort that does not resolve with time

• Significant changes in mood, including low mood or anxiety, which may be associated with rapid weight loss or hormonal shifts

• Noticeable and sustained changes in libido or sexual function that are causing distress

• Irregular menstrual cycles or new hormonal symptoms

• Symptoms of hypoglycaemia — shakiness, sweating, confusion, or palpitations — particularly if you are also taking insulin or a sulfonylurea

• Any injection site reactions that worsen, become infected, or do not resolve

• Concerns about dehydration or reduced urine output following persistent gastrointestinal symptoms

Changes in libido, whilst not confirmed as a direct side effect of retatrutide, are worth discussing with a GP if they are persistent, distressing, or accompanied by other symptoms. A GP can assess whether hormonal investigations are warranted — for example, checking testosterone, oestrogen, thyroid function, or prolactin levels — and can refer to an endocrinologist or sexual health specialist if appropriate.

Patients should never stop or adjust their medication without first consulting the prescribing clinician or trial investigator, as abrupt discontinuation may affect metabolic control and overall health outcomes. Anyone who is pregnant or planning a pregnancy should inform their clinician and trial team without delay.

Reporting Side Effects Through the MHRA Yellow Card Scheme

Suspected side effects from retatrutide used outside a clinical trial should be reported via the MHRA Yellow Card Scheme; trial participants must report adverse events directly to their trial team.

In the United Kingdom, the primary mechanism for reporting suspected adverse drug reactions outside of a clinical trial is the MHRA Yellow Card Scheme, accessible online at yellowcard.mhra.gov.uk. This pharmacovigilance system allows patients, carers, and healthcare professionals to report any suspected side effects from medicines, vaccines, and medical devices — including those that are unlicensed or used off-label.

If you are not enrolled in a clinical trial and have accessed retatrutide through another route, you are encouraged to report any suspected side effects via the Yellow Card Scheme. Reporting — even if you are uncertain whether the drug caused the symptom — is an important contribution to drug safety monitoring. The MHRA uses Yellow Card data to identify emerging safety signals, update prescribing guidance, and, where necessary, take regulatory action.

If you are participating in a clinical trial involving retatrutide, adverse events must be reported directly to the trial team in accordance with the study protocol. This is a legal requirement, and the trial investigators are responsible for reporting serious adverse events to the relevant regulatory authorities. You should not submit a Yellow Card report for events occurring within a clinical trial unless specifically instructed to do so by the study team.

Anyone can submit a Yellow Card report for non-trial use, including:

• Patients and members of the public

• GPs, pharmacists, nurses, and hospital clinicians

• Parents or carers reporting on behalf of another person

For general queries about medicines safety or to find out more about the Yellow Card Scheme, patients can contact the MHRA directly or speak to their GP or pharmacist. Staying informed and proactive about reporting contributes meaningfully to the safe development of new medicines for everyone.

Frequently Asked Questions